Answers are grounded in this paper and cite their sources.
The two moxifloxacin-containing regimens produced a more rapid initial decline in bacterial load, as compared with the control group. However, noninferiority for these regimens was not shown, which indicates that shortening treatment to 4 months was not effective in this setting. (Funded by the Global Alliance for TB Drug Development and others; REMoxTB ClinicalTrials.gov number, NCT00864383.).
No takes yet. Share an insight, caveat, or question.
Gillespie et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: